
Virtual Invitation

TNBC Indication SK006 PD-L1 IHC 22C3 pharmDx Launch

20 July 2022 | 2:00 p.m. GMT +7



TNBC Indication SK006 PD-L1 IHC 22C3 pharmDx Launch

Date: Wednesday, 20 July 2022 Location: Virtual Time: 2:00 p.m. - 3.00 p.m. GMT +7 Register here: <u>https://aglt.co/tnbcthailand</u>



For more information, please contact

Theerapat Pumma Medicare Supply Ltd. Part. 061 669 8013



Triple Negative Breast Cancer in Thailand

Every year, nearly 22,000 women in Thailand are reported to be diagnosed with breast cancer, with over 8000 of these cases ending in death.

Agilent is committed to fight cancer. Join us as we launch the latest indication on PD-L1 IHC 22C3 pharmDx for Triple Negative Breast Cancer (TNBC).



Opening address

Panadda Yanapirat Vice-President, Medicare Supply Ltd. Part. Moderator



Launch of TNBC: An overview of the new TNBC indication approved for PD-L1 IHC 22C3 pharmDx in Thailand

Stefanie Scheer Global Product Marketing, Agilent Technologies, Denmark



PD-L1 22C3 IHC Testing in Triple Negative Breast Cancer (TNBC) : Guiding Immune Checkpoint Inhibitor Therapy in Thailand

Dr. Kroonpong lampenkhae, MD. Main Consultant for Breast Pathology, King Chulalongkorn Memorial Hospital



D72115

This information is subject to change without notice.

© Agilent Technologies, Inc. 2022